Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A multi-step continuous flow synthesis of pomalidomide

A multi-step continuous flow synthesis of pomalidomide The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide are widely used to treat multiple myeloma. The permanent need of IMiDs analogues in clinical screening and practice has created the demand to find a reliable and robust method for their preparation. To reach this goal, the use of flow chemistry is quite appealing, allowing a safe operation, an excellent reproducibility and an efficient process. Herein, we describe a continuous 3–4 step flow approach for the synthesis of the pomalidomide (38–47% overall yield) and a few analogues.Graphical abstract[graphic not available: see fulltext] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Flow Chemistry Springer Journals

A multi-step continuous flow synthesis of pomalidomide

Loading next page...
 
/lp/springer-journals/a-multi-step-continuous-flow-synthesis-of-pomalidomide-R2rGywWSuU

References (20)

Publisher
Springer Journals
Copyright
Copyright © Akadémiai Kiadó 2022
ISSN
2062-249X
eISSN
2063-0212
DOI
10.1007/s41981-022-00223-3
Publisher site
See Article on Publisher Site

Abstract

The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide are widely used to treat multiple myeloma. The permanent need of IMiDs analogues in clinical screening and practice has created the demand to find a reliable and robust method for their preparation. To reach this goal, the use of flow chemistry is quite appealing, allowing a safe operation, an excellent reproducibility and an efficient process. Herein, we describe a continuous 3–4 step flow approach for the synthesis of the pomalidomide (38–47% overall yield) and a few analogues.Graphical abstract[graphic not available: see fulltext]

Journal

Journal of Flow ChemistrySpringer Journals

Published: Dec 1, 2022

Keywords: Active pharmaceutical ingredients; IMiDs; Thalidomide; Glutamine; Reduction

There are no references for this article.